PD-1 Inhibitor Falls Short in Triple-Negative Breast Cancer No survival benefit with pembrolizumab vs chemotherapy in second-, third-line treatment Mar 08, 2021
Entrectinib Impresses in Certain Lung Cancers Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
Mammo Study: One Saves Lives, More Exams Save More Lives Risk of fatal breast cancer decreases with increasing participation in screening Mar 02, 2021
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
A CLEAR Upfront Winner in Advanced RCC? Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date Feb 14, 2021
Practice-Changing Trial in Metastatic Papillary RCC Cabozantinib improved PFS, response rates over sunitinib Feb 14, 2021
New Standard in High-Risk Muscle-Invasive Bladder Cancer? Adjuvant nivolumab improves DFS in all comers, PD-L1 population Feb 13, 2021
New Drug OK'd for Chemo-Induced Myelosuppression in SCLC CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancer Large proportion of intermediate- to high-risk patients could avoid aggressive therapy Feb 12, 2021
Survival Boost in Bladder Cancer With Antibody-Drug Conjugate Four-month absolute improvement with enfortumab vedotin in previously treated disease Feb 12, 2021
Radionuclide Tx Wins in Third-Line Metastatic CRPC Early trial shows improved PFS, response rates versus cabazitaxel Feb 11, 2021
Hit and Miss in Castration-Resistant Prostate Cancer No OS benefit with apalutamide-abiraterone, despite improved PFS Feb 11, 2021
Want Data on Recently Approved Actinic Keratosis Drug? Here You Go Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
First Immunotherapy Approved for Basal Cell Carcinoma Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
FDA Panel Slows the Roll for Pembrolizumab in Breast Cancer Advisory committee: Wait for more data before considering neoadjuvant indication Feb 09, 2021
Has Pembrolizumab Finally Met an Indication FDA Doesn't Like? Agency staff skeptical of data in early breast cancer Feb 08, 2021
Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
Brain Tumor Risk Upped With Synthetic Progestogen Absolute risk still low, however, and product not currently approved in U.S. Feb 03, 2021
Optimizing Neoadjuvant Therapy for Breast Cancer ASCO guideline covers patient selection, treatment options, follow-up Feb 02, 2021
Dustin Diamond's Small Cell Lung Cancer "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
KRAS Inhibitor Continues to Impress in NSCLC Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
Nab-Paclitaxel as Possible Option for Relapsed NSCLC Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
AGA Updates Guidelines for Refractory H. Pylori New info stresses knowing patients' antibiotic exposure and doing drug susceptibility testing Feb 01, 2021
Should COVID-Strained Centers Hit Pause on Lung Cancer Screening? A debate on what stopping scans would do to health systems, patients Feb 01, 2021
Promising Data for Preop Checkpoint Inhibition in NSCLC Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
Dual Checkpoint Blockade No Help in PD-L1-High NSCLC Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
Preventive Approach to C-Section Bleeding Pans Out in Trial Treatment lowered risk of early blood loss and transfusion, but not more severe hemorrhage Jan 29, 2021
Whole-Pelvis Tops Prostate-Only RT in High-Risk Disease Practice impact may hinge on knowledge versus clinical bias Jan 28, 2021
Officials Investigate Physician's Death After COVID Vaccination Onset of rare blood disorder should not be interpreted as causal, experts say Jan 27, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
Telehealth's Security Problem; Virtual Cancer Care; Post-Pandemic Teladoc Emerging trends in telemedicine and telehealth Jan 25, 2021
Ozempic Seeking High Dose OK; Thyroid Cancer Overdiagnosed in Kids? News and commentary from the endocrinology world Jan 24, 2021
Aspirin and CRC Risk: A Curious Age Connection Implications for prophylactic recommendations, researchers say Jan 21, 2021
Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
Kardashian Makeup Artist Hrush Achemyan's Ovarian Cancer Beauty influencer reveals diagnosis Jan 21, 2021
